Analyzing Immunome (NASDAQ:IMNM) and Nutra Pharma (OTCMKTS:NPHC)

Nutra Pharma (OTCMKTS:NPHC) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings for Nutra Pharma and Immunome, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutra Pharma	0	0	0	0	0.00
Immunome	1	0	12	0	2.85

Immunome has a consensus target price of $34.18, suggesting a potential upside of 36.56%. Given Immunome’s stronger consensus rating and higher probable upside, analysts clearly believe Immunome is more favorable than Nutra Pharma.

Insider and Institutional Ownership

44.6% of Immunome shares are owned by institutional investors. 61.5% of Nutra Pharma shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Nutra Pharma and Immunome’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutra Pharma	-364.90%	N/A	-159.08%
Immunome	N/A	-51.15%	-47.32%

Volatility and Risk

Nutra Pharma has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Immunome has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500.

Earnings and Valuation

This table compares Nutra Pharma and Immunome”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutra Pharma	$380,000.00	1.88	-$2.05 million	N/A	N/A
Immunome	$6.94 million	408.45	-$212.39 million	($2.38)	-10.52

Nutra Pharma has higher earnings, but lower revenue than Immunome.

Summary

Immunome beats Nutra Pharma on 9 of the 12 factors compared between the two stocks.

About Nutra Pharma

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.